REVIEW. Servicio de Hematología, Unidad de Enfermedades Infecciosas and Servicio de Microbiología, Hospital Universitario La Fe, Valencia, Spain
|
|
- Rosa Ward
- 5 years ago
- Views:
Transcription
1 REVIEW Epidemiology of invasive fungal infections due to Aspergillus spp. and Zygomycetes M. A. Sanz Alonso, I. Jarque Ramos, M. Salavert Lletí, J. Pemán Servicio de Hematología, Unidad de Enfermedades Infecciosas and Servicio de Microbiología, Hospital Universitario La Fe, Valencia, Spain ABSTRACT An increased incidence of invasive fungal infections, especially those caused by filamentous fungi, has been observed among high-risk patients such as allogeneic stem-cell transplant recipients and those with acute leukaemia receiving high-dose chemotherapy. Despite significant progress in the prevention and treatment of fungal infections, invasive aspergillosis continues to be a major cause of morbidity and mortality. Development of more efficient therapeutic and prophylactic strategies with currently available and new antifungal agents, as well as of sensitive and specific methods for early diagnosis, is needed. In addition, an increasing incidence of invasive infections caused by Zygomycetes is of concern. Several reports of breakthrough zygomycosis in patients receiving voriconazole have raised the possibility of a relationship between voriconazole use and increased risk of Zygomycetes infection, although evidence of a definite causal relationship remains controversial. The potential impact that all therapeutic and prophylactic changes can have on the emergence of new pathogens should be kept in mind. Keywords Invasive fungal infections, Aspergillus, zygomycetes Clin Microbiol Infect 2006; 12 (suppl 7): 2 6 INTRODUCTION An increased incidence of invasive fungal infections has been particularly evident in patients with cancer over the past decades, particularly in haematopoietic stem-cell transplant recipients and patients with haematological malignancies [1 7]. In addition, a marked shift in the spectrum of causative organisms is increasingly being reported, with filamentous fungi gaining predominance. Indeed, until the 1990s, candidiasis was the most common invasive fungal infection in neutropenic patients, whereas during the past decade, invasive mould infections have become the most frequent fungal infections among patients at high risk, especially those receiving allogeneic stem-cell transplants or very intensive chemotherapy for acute leukaemias [8,9]. Although several explanations can be given for Corresponding author and reprints: M. A. Sanz, Servicio de Hematología, Hospital Universitario La Fe, Avenue. Campanar 21, Valencia, Spain msanz@uv.es this radical change in the prevalence of fungi in invasive mycoses, the routine use of fluconazole prophylaxis, the increased intensity of chemotherapy, and the growing practice of allogeneic stem-cell transplantation from unrelated donors over the past decade, among other factors, clearly seem to be involved. In addition, although Aspergillus spp. account for the majority of invasive filamentous fungal infections, other emerging opportunistic fungal pathogens have been reported over the last 20 years [10 12]. The present review summarises some of the new developments in the epidemiology of invasive aspergillosis and zygomycosis. EPIDEMIOLOGY OF ASPERGILLOSIS Currently, invasive aspergillosis is probably the major clinical problem among invasive fungal infections. Although underlying conditions predisposing to this infectious complication include malignancy, haematopoietic stem-cell or solidorgan transplantation, and congenital or acquired immunodeficiencies, the present review focuses Ó 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
2 Sanz Alonso et al. Epidemiology of Aspergillus and Zygomycetes infections 3 on epidemiological considerations in patients with haematological malignancies and in haematopoietic stem-cell transplant recipients, in whom invasive aspergillosis is the most prevalent mould infection and a major cause of morbidity and mortality. During the last decade, several epidemiological factors have contributed to the increasing concern about invasive aspergillosis. Several reports have shown a rising prevalence of invasive aspergillosis upon autopsy over recent decades worldwide [13 17], surpassing invasive candidiasis as the most frequent fungal infection found at autopsy at some tertiary-care centres [1,15 17]. Moreover, this epidemiological increase in the incidence of aspergillosis and the decrease in candidiasis have been widely reported, not only at autopsy, but also upon evaluation of microbiological isolates from patients with a diagnosis of possible, probable or proven invasive fungal infection. The routine prophylactic use of fluconazole over the past decade is certainly implicated in the dramatic decrease in the incidence of invasive candidiasis, and has also contributed substantially to the emergence of invasive aspergillosis as the most common invasive fungal infection [16]. We have observed similar epidemiological changes in our Leukaemia and Stem Cell Transplant Unit at the University Hospital La Fe. We identified 131 cases of invasive aspergillosis between January 1988 and December 2003 (Fig. 1). During the first half of this period, the incidence of invasive aspergillosis was relatively stable at 25 cases per 1000 admissions, while in the last 8 years it has continuously increased. Acute leukaemia and allogeneic haematopoetic stem-cell transplantation are also the most frequent underlying conditions in our Haematology Unit. Although several factors may have been involved in the increase in the incidence, it should be noted that the number of allogeneic stem-cell transplants, especially those using bone marrow and cord blood from unrelated donors as the source of stem cells, has significantly increased at our institution during recent years. Among 407 stem-cell transplants performed from 1999 to 2003, the overall incidence of invasive aspergillosis was 6.8%, but it has dramatically increased from less than 2 per 100 transplants during the first 3 years to 17.5 per 100 transplants during the last year (Fig. 2). We can speculate about a possible nosocomial cluster associated with hospital construction works, defects in airhandling equipment, and other environmental factors; however, the number of cases may sometimes appear to be a cluster when in fact it is not [17]. Although it is still too early to evaluate the individual impact of several measures that were implemented almost simultaneously to decrease the incidence of aspergillosis in our unit, it seems that the introduction of systematic itraconazole prophylaxis for patients with acute leukaemia and for allogeneic stem-cell transplant recipients has certainly contributed to the attainment of a significant reduction (unpublished data). Although the incidence of invasive aspergillosis in other haematological malignancies, e.g., multiple myeloma, non-hodgkin s lymphoma, and other lymphoproliferative diseases, is much Fig. 1. Trends in fungal infections (probable and proven cases) in the Haematology Service at University Hospital La Fe over a 15-year period. Fluco-S: Fluconazole-susceptible; Fluco-R: Fluconazole-resistant. Incidence (per 100 SCT) Year Fig. 2. Incidence of aspergillosis in stem-cell transplant (SCT) recipients in the Haematology Service at University Hospital La Fe ( ).
3 4 Clinical Microbiology and Infection, Volume 12 Supplement 7, 2006 less than that reported in patients with acute leukaemia, an increase in opportunistic infections has been also suggested, including invasive fungal infections, in parallel with the use of more aggressive therapeutic approaches during recent years. The use of more intensive chemotherapy and highly immunosuppressive drugs, e.g., fludarabine or alemtuzumab, has certainly contributed to an improved outcome of lymphoproliferative diseases, but it has also increased the risk of opportunistic infections, including invasive aspergillosis. It is generally accepted that the epidemiology of invasive aspergillosis is complex and that many epidemiological issues still remain controversial. Regarding the nosocomial or communityacquired origin of this particular fungal infection, it is assumed that most cases of invasive aspergillosis in immunocompromised hosts are of nosocomial origin, the air being the most important source of Aspergillus. However, the proportion of patients who become infected from alternative sources has not been well-determined. In fact, a considerable number of cases of invasive aspergillosis in allogeneic stem-cell transplant recipients occur in the outpatient setting. In these patients, who are severely immunosuppressed for prolonged periods after engraftment, with alternating periods of hospitalisation and home residence, but always under potent immunosuppressive therapies, it is very difficult to establish the actual origin of the infection in individual cases. To add to the complexity of and the concern about the potential sources of Aspergillus contamination, a recent study found that cotton fabric harbours and disperses Aspergillus spores more readily than other types of fabric [18]. This finding leads us to speculate that cotton clothing worn by hospital personnel and visitors may serve as a source of Aspergillus exposure for susceptible patients [1]. Finally, as Kontoyiannis and Bodey reported recently [1], the available epidemiological evidence implicating the hospital water reservoir systems in the acquisition of nosocomial invasive aspergillosis is weak [19] and still remains controversial [20]. Despite the significant progress in the treatment of invasive aspergillosis, the mortality rate is still high and the financial burden of invasive aspergillosis-associated hospitalisation is enormous. EPIDEMIOLOGY OF ZYGOMYCOSIS Within the class Zygomycetes, the order Mucorales includes the genera Rhizopus, Mucor and Rhizomucor, which are the pathogens most frequently implicated in human zygomycosis. Several recent reports have called attention to the increase in the incidence of invasive infections caused by the Zygomycetes, particularly in recipients of haematopoietic stem-cell transplants and patients with haematological malignancies. However, contrasting with infection by other filamentous fungi that mainly target immunocompromised hosts, zygomycosis is frequently observed in a broader population of patients, including those with poorly controlled diabetes mellitus, and those receiving deferoxamine therapy for iron overload, among others [2]. As with aspergillosis, the present review focuses on epidemiological considerations in patients with haematological malignancies and in haematopoietic stem-cell transplant recipients. The epidemiology and outcome of this emerging life-threatening fungal infection have been outstandingly reviewed recently by Roden et al. [2] This is the first comprehensive review in the English-language literature concerning zygomycosis since the original case report in This review analyses 929 eligible cases in whom the zygomycosis had been confirmed either histologically or by culture, and describes the underlying condition, the anatomical location of infection, the surgical and antifungal treatments, and the outcome. Although the first reported case of zygomycosis was in 1885 [21], the first eligible case that met the predefined criteria was reported in One of the most striking observations during the course of writing this review was that diabetes was the most common underlying condition (36%), and the next largest patient population had no primary underlying disease (19%). Furthermore, malignancy was an underlying condition in the third largest patient population (17%), with haematological malignancy being the underlying condition in 95% of these cases. Regarding the sites and patterns of infection, there were significant differences according to the host population. The patterns observed in patients with malignancy and in stem-cell transplant recipients are shown in Table 1. The lungs constituted more than one-half of all sites of infection in patients
4 Sanz Alonso et al. Epidemiology of Aspergillus and Zygomycetes infections 5 Table 1. Patterns of zygomycosis in different haematological conditions (data from Roden et al. [2]) Type of infection, by site Malignancy (%) Stem cell transplantation (%) Sinus Sinusitis Rhino-cerebral 4 11 Sino-orbital 5 5 Pulmonary Cutaneous 12 9 Gastrointestinal 3 2 Other 6 5 with malignancy and in stem-cell transplant recipients (60% and 52%, respectively), while sinuses were the second most common site involved in these patients. Rhizopus and Mucor were the most commonly recovered genera (50% and 18%, respectively). In this study, zygomycosis was apparently more prevalent among males. Finally, multivariate regression analysis of risk-factors showed that disseminated disease, renal failure and infection with Cunninghamella species had an adverse influence on mortality. Pulmonary, rhino-cerebral, kidney and gastrointestinal infection were associated with the highest risk of mortality. Recently, attention has been called to the possible association of voriconazole with an increased risk of infection caused by Zygomycetes [12]. This association is supported by several reports of breakthrough zygomycosis in patients receiving voriconazole [22 26]. Voriconazole has broad-spectrum antifungal activity and is especially active against Aspergillus species and other filamentous fungi, but it has no activity against the Zygomycetes [27]. However, a definite causal relationship between treatment with voriconazole and the emergence of breakthrough infections caused by Zygomycetes is far from established. In fact, although the use of voriconazole may have contributed to the occurrence of zygomycosis, there are some data indicating that the incidence of zygomycosis was increasing before the introduction of voriconazole into clinical practice [12]. Data from two large transplant centres in the USA show that an increase in the incidence of zygomycosis was already apparent in the mid-1990s [28,29], leading to speculation that the apparent increase in the incidence of zygomycosis may be an amplification of this phenomenon [12]. However, a recent prospective surveillance study of 27 patients with zygomycosis (case-control observational study) carried out at the MD Anderson Cancer Center found that voriconazole prophylaxis was a factor that favoured zygomycosis [30]. CONCLUSIONS In the context of an increasing incidence of invasive fungal infections in patients with haematological malignancies and in haematopoietic stem-cell transplant recipients, filamentous fungi have increasingly been reported as the causative organisms over the past decade. Despite significant progress in the prevention and treatment of fungal infections, invasive aspergillosis is still a major cause of morbidity and mortality in these patients. More efficient therapeutic and prophylactic strategies, involving the currently available antifungal agents and new antifungal agents, as well as sensitive and specific methods for early diagnosis, are needed. The potential impact that therapeutic and prophylactic changes can have on the emergence of new pathogens should be kept in mind. For example, the possible association of the use of voriconazole and an increased risk of infection caused by resistant organisms such as Zygomycetes has been reported recently. REFERENCES 1. Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis 2002; 21: Roden MM, Zaoutis TE, Buchanan WL et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41: Pagano L, Girmenia C, Mele L et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica 2001; 86: Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis 1995; 21: Walsh TJ, De Pauw B, Anaissie E, Martino P. Recent advances in the epidemiology, prevention and treatment of invasive fungal infections in neutropenic patients. J Med Vet Mycol 1994; 32: Manuel RJ, Kibbler CC. The epidemiology and prevention of invasive aspergillosis. J Hosp Infect 1998; 39: Bodey G, Bueltmann B, Duguid W et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis 1992; 11:
5 6 Clinical Microbiology and Infection, Volume 12 Supplement 7, Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the post-mortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years experience at a cancer center and implications for management. Blood 1997; 90: Girmenia C, Pagano L, Corvatta L, Mele L, del Favero A, Martino P. The epidemiology of fusariosis in patients with haematological diseases. GIMEMA Infection Programme. Br J Haematol 2000; 11: Kauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: Groll AH, Shah PM, Menzel C, Schneider M, Just-Muebling G, Hubner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33: Yamazaki T, Kume H, Murase S, Yamshita E, Arisawa M. Epidemiology of visceral mycoses: analysis of data in annual of the pathological autopsy cases in Japan. J Clin Microbiol 1999; 37: Vogeser M, Haas A, Aust D, Ruckdeschel G. Postmortem analysis of invasive aspergillosis in a tertiary care hospital. Eur J Clin Microbiol Infect Dis 1997; 16: Van Burik JH, Leisenring W, Myerson D et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients, with special attention to hepatic candidiasis. Medicine 1998; 77: Chandrasekar PH, Alangaden G, Manavathu E. Aspergillus: an increasing problem in tertiary care hospitals? Clin Infect Dis 2000; 30: Fox JL. Clothing spread Aspergillus spores. Curr Topics Am Soc Microbiol (ASM) News 2001; 67: Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment rethinking our approach to prevention. Clin Infect Dis 2001; 33: Anaissie EJ, Costa SF. Nosocomial aspergillosis is waterborne. Clin Infect Dis 2001; 33: Paultauf A. Mycosis mucorina. Arch Path Anat 1885; 102: Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. N Engl J Med 2004; 350: Siwek GT, Dodgson KJ, De Magalhaes-Silverman M et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: Imhof A, Balajee SA, Fredricks DN et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: Vigouroux S, Morin O, Moreau P et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005; 40: Oren I. Breakthrough zygomycosis during empirical voriconazole therapy in febrile patients with neutropenia. Clin Infect Dis 2005; 40: Gómez-López A, Cuenca-Estrella M, Monzón A, Rodríguez-Tudela JL. In vitro susceptibility of clinical isolates of Zygomycota to amphotericin B, flucytosine, itraconazole, and voriconazole. J Antimicrob Chemother 2001; 48: Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. Zygomycosis in the 1990s in tertiary-care cancer center. Clin Infect Dis 2000; 30: Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: Kontoyiannis DP, Lionakis MS, Lewis RE et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005; 191:
Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan
J Infect Chemother (2013) 19:946 950 DOI 10.1007/s10156-013-0624-7 ORIGINAL ARTICLE Nationwide survey of treatment for pediatric patients with invasive fungal infections in Japan Masaaki Mori Received:
More informationItraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston
REVIEW Itraconazole vs. fluconazole for antifungal prophylaxis in allogeneic stem-cell transplant patients D. J. Winston Division of Hematology-Oncology, Department of Medicine, UCLA Medical Center, Los
More informationAntifungal Agents - Cresemba (isavuconazonium), Vfend. Prior Authorization Program Summary
Antifungal Agents - Cresemba (isavuconazonium), Noxafil (posaconazole), Vfend (voriconazole) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2,14 Drug FDA Indication(s) Dosing Cresemba
More informationmycoses Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Summary Introduction
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Prospective antifungal therapy (PATH) alliance â : focus on mucormycosis Dimitrios P. Kontoyiannis, 1 Nkechi Azie, 2 Billy
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationamphotericin B empiric therapy; preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET
4 17 9 27 17 1 7 amphotericin B 34 empiric therapy; ET preemptive therapy presumptive therapy Preemptive therapy Presumptive therapy ET targeted therapy ET Key words: antifungal therapyempiric therapypreemptive
More informationAntifungals in Invasive Fungal Infections: Antifungals in neutropenic patients
BVIKM-SBIMC La Hulpe, 6 November 2008 Antifungals in Invasive Fungal Infections: Antifungals in neutropenic patients Johan Maertens, MD Acute Leukemia and SCT Unit University Hospital Gasthuisberg Catholic
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationVoriconazole October 2015 Risk Management Plan. Voriconazole
Voriconazole October 2015 VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Invasive aspergillosis (IA) is the most devastating of Aspergillus related diseases, targeting severely
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationDiagnosis,Therapy and Prophylaxis of Fungal Diseases
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationInvasive zygomycosis in neonates and children
REVIEW 10.1111/j.1469-0691.2009.02981.x Invasive zygomycosis in neonates and children E. Roilides 1,2, T. E. Zaoutis 3 5 and T. J. Walsh 2 1) 3rd Department of Paediatrics, Aristotle University, Thessaloniki,
More informationPROGRESSI NELLA TERAPIA ANTIFUNGINA. A tribute to Piero Martino
PROGRESSI NELLA TERAPIA ANTIFUNGINA A tribute to Piero Martino 1946-2007 ITALIAN ICONS IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI IERI, OGGI, E DOMANI 1961 CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES
More informationUse of Antifungal Drugs in the Year 2006"
Use of Antifungal Drugs in the Year 2006" Jose G. Montoya, MD Associate Professor of Medicine Associate Chief for Clinical Affairs Division of Infectious Diseases Stanford University School of Medicine
More informationFungal infections in ICU. Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia
Fungal infections in ICU Tang Swee Fong Department of Paediatrics Universiti Kebangsaan Malaysia Epidemiology of invasive fungal infections - US +300% Martin GS, et al. N Engl J Med 2003;348:1546-1554
More informationASPERGILLOSIS IN THE NON-NEUTROPENIC HOST
ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST Dr J Garbino University Hospital Geneva ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST INTRODUCTION SWISS ASPERGILLOSIS SURVEY IN THE NON-NEUTROPENIC HOST Introduction
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationTrends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients. Saturday, April 18, 2015 Charlottetown, P.E.I.
Trends in Invasive Fungal Infection (IFI) in Haematology-Oncology Patients Saturday, April 18, 2015 Charlottetown, P.E.I. Moderator & Speaker: Shariq Haider MD, FRCPC, FACP, CCST(UK), DTMH(UK) Professor
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Voriconazole Effective Date... 3/15/2018 Next Review Date... 3/15/2019 Coverage Policy Number... 4004 Table of Contents Coverage Policy... 1 General Background...
More informationAntifungal prophylaxis in haematology patients: the role of voriconazole
REVIEW 10.1111/j.1469-0691.2012.03772.x Antifungal prophylaxis in haematology patients: the role of voriconazole Y. Hicheri 1, G. Cook 2 and C. Cordonnier 1 1) Service d Hématologie Clinique, Assistance
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationEmerging Fungal Diseases
INVITED ARTICLE EMERGING INFECTIONS Larry J. Strausbaugh, Section Editor Emerging Fungal Diseases Marcio Nucci 1 and Kieren A. Marr 2,3 1 University Hospital, Universidade Federal do Rio de Janeiro, Rio
More informationTIMM 2013 Role of non-culture biomarkers for detection of fungal infections
TIMM 2013 Role of non-culture biomarkers for detection of fungal infections Tom Rogers Clinical Microbiology, Trinity College Dublin Tom Rogers, TCD & St James s Hospital Dublin, Ireland FACTORS INFLUENCING
More informationMANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS
MANAGEMENT OF HOSPITAL-ACQUIRED FUNGAL INFECTIONS Paul D. Holtom, MD Associate Professor of Medicine and Orthopaedics USC Keck School of Medicine Numbers of Cases of Sepsis in the United States, According
More informationposaconazole, or prayers
Antifungal therapy: Polyenes, posaconazole, or prayers Michael Kleinberg, MD, PhD Associate Professor of Medicine Head, Infectious Diseases Section Marlene and Stewart Greenebaum Cancer Center University
More informationHepatosplenic Candidiasis in Patients with Acute Leukemia: Incidence and Prognostic Implications
375 Hepatosplenic Candidiasis in Patients with Acute Leukemia: Incidence and Prognostic Implications Veli-Jukka Anttila, Erkki Elonen, Stig Nordling, From the Department of Medicine, Divisions of Hematology
More informationCombination Antifungal Therapy for Invasive Aspergillosis
MAJOR ARTICLE Combination Antifungal Therapy for Invasive Aspergillosis Kieren A. Marr, 1,2 Michael Boeckh, 1,2 Rachel A. Carter, 1 Hyung Woo Kim, 1 and Lawrence Corey 1,2 1 Fred Hutchinson Cancer Research
More informationProphylactic Strategies for Invasive Fungal Diseases in Hematological Stem Cell Transplantation: An Update
DOI 10.6314/JIMT.201802_29(1).05 2018 29 38-45 Prophylactic Strategies for Invasive Fungal Diseases in Hematological Stem Cell Transplantation: An Update Alice Ying-Jung Wu 1, Hsiang-Kuang Tseng 1,2, and
More informationCase Report. Hypertension as the Presentation of Disseminated Rhizopus in an Infant with Acute Myeloid Leukaemia
HK J Paediatr (new series) 2018;23:29-33 Case Report Hypertension as the Presentation of Disseminated Rhizopus in an Infant with Acute Myeloid Leukaemia FL HUANG, CF LIN, PY CHEN, TK CHANG Abstract Key
More informationMucormycosis in renal transplant recipients: review of 174 reported cases
Song et al. BMC Infectious Diseases (2017) 17:283 DOI 10.1186/s12879-017-2381-1 RESEARCH ARTICLE Open Access Mucormycosis in renal transplant recipients: review of 174 reported cases Yan Song 1, Jianjun
More informationThe Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY
The Hospital for Sick Children Technology Assessment at Sick Kids (TASK) EXECUTIVE SUMMARY CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL
More informationCURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS. Dr AMIT RAODEO DM SEMINAR
CURRENT AND NEWER ANTI-FUNGAL THERAPIES- MECHANISMS, INDICATIONS, LIMITATIONS AND PROBLEMS Dr AMIT RAODEO DM SEMINAR Introduction The incidence of invasive fungal infections in critically ill intensive
More informationHema e-chart Registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections
ORIGINAL ARTICLE MYCOLOGY Hema e-chart Registry of invasive fungal infections in haematological patients: improved outcome in recent years in mould infections A. M. Nosari 1, M. Caira 2, M. L. Pioltelli
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationManagement Strategies For Invasive Mycoses: An MD Anderson Perspective
Management Strategies For Invasive Mycoses: An MD Anderson Perspective Dimitrios P. Kontoyiannis, MD, ScD, FACP, FIDSA Professor of Medicine Director of Mycology Research Program M. D. Anderson Cancer
More informationManagement of fungal infection
Management of fungal infection HKDU symposium 17 th May 2015 Speaker: Dr. Thomas Chan MBBS (Hons), MRCP, FHKCP, FHKAM Synopsis Infection caused by fungus mycoses Skin infection by fungus is common in general
More informationProphylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy?
TIMM-4 18-21 October 2009 Athens, Greece Prophylaxis, Empirical, Pre-emptive Therapy of Aspergillosis in Hematological Patients: Which Strategy? www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology
More informationNew Directions in Invasive Fungal Disease: Therapeutic Considerations
New Directions in Invasive Fungal Disease: Therapeutic Considerations Coleman Rotstein, MD, FRCPC, FACP University of Toronto University Health Network Toronto, Ontario Disclosure Statement for Coleman
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationCLINICAL RESEARCH. Drew J. Winston, Kathy Bartoni, Mary C. Territo, Gary J. Schiller
CLINICAL RESEARCH Efficacy, Safety, and Breakthrough Infections Associated with Standard Long-Term Posaconazole Antifungal Prophylaxis in Allogeneic Stem Cell Transplantation Recipients Drew J. Winston,
More informationMycological Profile of Bronchial Wash Specimens in Patients with Lower Respiratory Tract Infections
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 11 (2017) pp. 176-182 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.611.022
More informationAntifungal Pharmacodynamics A Strategy to Optimize Efficacy
Antifungal Pharmacodynamics A Strategy to Optimize Efficacy David Andes, MD Associate Professor, Department of Medicine Division of Infectious Diseases Medical Microbiology and Immunology University of
More informationMucor Mycosis maxilla with palatal destruction An Interesting Case Report with Literature Review
ISSN 2250-0359 Volume 3 Issue 3.5 2013 Mucor Mycosis maxilla with palatal destruction An Interesting Case Report with Literature Review 1 Balasubramanian Thiagarajan 2 Venkatesan Ulaganathan 1 Stanley
More informationAntifungals and current treatment guidelines in pediatrics and neonatology
Dragana Janic Antifungals and current treatment guidelines in pediatrics and neonatology Dragana Janic. University Children`s Hospital, Belgrade, Serbia 10/10/17 Hotel Crowne Plaza, Belgrade, Serbia; www.dtfd.org
More informationAbstract. Introduction
ORIGINAL ARTICLE MYCOLOGY The incidence and risk factors of invasive fungal infection after haploidentical haematopoietic stem cell transplantation without in vitro T-cell depletion Y.-Q. Sun, L.-P. Xu,
More informationFungal infections. Ematologia. Corrado Girmenia. Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy
Fungal infections Corrado Girmenia Ematologia, Azienda Policlinico Umberto I Sapienza University of Rome, Italy Ematologia Epidemiology Diagnostic approach Prevention strategies Monitoring of IFDs in
More informationChallenges and controversies of Invasive fungal Infections
Challenges and controversies of Invasive fungal Infections Mona Al-Dabbagh, MD, MHSc Assistant Professor of Pediatrics, COM-KSAU-HS Consultant Pediatric Infectious Diseases and Transplant Infectious Diseases
More informationLe infezioni fungine nel trapianto di cellule staminali emopoietiche. Claudio Viscoli Professor of Infectious Disease University of Genova, Italy
Le infezioni fungine nel trapianto di cellule staminali emopoietiche Claudio Viscoli Professor of Infectious Disease University of Genova, Italy Potential conflicts of interest Received grants as speaker/moderator
More informationAbstract. Introduction. Editor: M. Paul
ORIGINAL ARTICLE MYCOLOGY Incidence of invasive fungal disease after unmanipulated haploidentical stem cell transplantation was significantly higher than that after HLA-matched sibling transplantation
More informationS. Perkhofer, C. Lass-Flörl, M. Hell, G. Russ, R. Krause, M. Hönigl, C. Geltner, J. Auberger, G. Gastl, M. Mitterbauer, et al.
The Nationwide Austrian Registry: a prospective data collection on epidemiology; therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients S. Perkhofer, C.
More informationDifficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies
Difficulties with Fungal Infections in Acute Myelogenous Leukemia Patients: Immune Enhancement Strategies Amar Safdar The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA Key Words.
More informationIn Vitro Interactions of Antifungal agents and Tacrolimus against Aspergillus Biofilms
AAC Accepted Manuscript Posted Online 24 August 2015 Antimicrob. Agents Chemother. doi:10.1128/aac.01510-15 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 In Vitro Interactions
More informationInvasive Aspergillosis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Analysis
BJID 2008; 12 (October) 385 Invasive Aspergillosis in Hematopoietic Stem Cell Transplant Recipients: A Retrospective Analysis Viviane Maria Hessel Carvalho-Dias 1, Caroline Bonamin Santos Sola 1, Clóvis
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More information1. Pre-emptive therapy. colonization, colonization, pre-emptive therapy. , ICU colonization. colonization. 2, C. albicans
Jpn. J. Med. Mycol. Vol. 45, 217 221, 2004 ISSN 0916 4804,.,, colonization, pre-emptive therapy. 2, non-albicans Candida., fluconazole.,. Key words: postoperative infection, non-albicans Candida, pre-emptive
More informationLondon New Drugs Group APC/DTC Briefing
London New Drugs Group APC/DTC Briefing Posaconazole for invasive fungal infections Contents Background 2 Dosing Information 3 Clinical evidence for treatment of infections 3 Clinical evidence for prophyactic
More informationWhat have we learned about systemic antifungals currently available on the market?
2nd ECMM/CEMM Workshop Milano, September 25, 2010 What have we learned about systemic antifungals currently available on the market? Prof. Dr. Georg Maschmeyer Dept. of Hematology, Oncology & Palliative
More informationEpidemiology and ecology of fungal diseases
Epidemiology and ecology of fungal diseases Healthcare Focus on: - individual - diagnosis - treatment Public Health Focus on: - population - prevention The nature of fungi Kingdom Fungi (lat. fungus, -i)
More informationControversies in management: prophylaxis or diagnostics
5 th Advances Against Aspergillosis Controversies in management: prophylaxis or diagnostics Caveats in the use of biological markers for early diagnosis Drosos E. Karageorgopoulos, MD Researcher, Alfa
More informationDepartment of Pediatric Hematology/Oncology, University Children s Hospital Tübingen, Hoppe-Seyler-Strß 1, Tübingen, Germany 2
Case Reports in Transplantation Volume 2012, Article ID 672923, 4 pages doi:10.1155/2012/672923 Case Report Eradication of Pulmonary Aspergillosis in an Adolescent Patient Undergoing Three Allogeneic Stem
More informationADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS
ADEQUATE ANTIFUNGAL USE FOR BLOODSTREAM INFECTIONS COMMERCIAL RELATIONS DISCLOSURE 2500 9000 15000 Astellas Gilead Sciences Pfizer Inc Expert advice Speaker s bureau Speaker s bureau OUTLINE OF THE PRESENTATION
More informationCancer Medicine. Introduction. Open Access ORIGINAL RESEARCH
Cancer Medicine ORIGINAL RESEARCH Open Access Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology oncology patients: a retrospective cohort study Hsiang-Chi
More informationForm 2046 R3.0: Fungal Infection Pre-HSCT Date
Key Fields Sequence Number: Date Received: - - CIBMTR Center Number: CIBMTR Recipient ID: Today's Date: - - Date of HSCT for which this form is being completed: - - HSCT type: (check all that apply) Autologous
More informationZygomycosesn existent plus.! Kwon-Chung et al. CID 2012
Zygomycosesn existent plus.! < Kwon-Chung et al. CID 2012 < Epidemiologyand treatmentof mucormycosis Olivier Lortholary, M.D.; Ph.D. Université Paris Descartes, Service de Maladies Infectieuses et Tropicales
More informationInvasive aspergillosis (IA) has emerged as a major cause of morbidity. Aspergillus terreus
1594 Aspergillus terreus An Emerging Amphotericin B Resistant Opportunistic Mold in Patients with Hematologic Malignancies Ray Y. Hachem, M.D. 1 Dimitrios P. Kontoyiannis, M.D., Sc.D. 1 Maha R. Boktour,
More informationFungal Infections in Neutropenic Hematological Disorders
Fungal Infections in Neutropenic Hematological Disorders 23 Dr Farah Jijina 24 Fungal Infections in Neutropenic Hematological Disorders 25 Dr Farah Jijina 26 Fungal Infections in Neutropenic Hematological
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE RHINOCEREBRAL MUCORMYCOSIS DUE TO RHIZOPUS IN A RECENTLY DIAGNOSED DIABETIC FEMALE: A CASE REPORT KULKARNI KV 1, PATHAK NP 2 1. Assistant
More informationAspergillus niger infection in patients with haematological diseases: a report of eight cases
Case report Aspergillus niger infection in patients with haematological diseases: a report of eight cases Fallbericht. Aspergillus niger-infektionen bei Patienten mit hämatologischen Erkrankungen L. Fianchi,
More informationCurrent options of antifungal therapy in invasive candidiasis
Current options of antifungal therapy in invasive candidiasis Saloua Ladeb Bone Marrow Transplant Center Tunis HAMMAMET 24 th April 2012 DEFINITION One or more positive results on blood culture for Candida
More informationMicafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version February 2013
Micafungin and Candida spp. Rationale for the EUCAST clinical breakpoints. Version 1.0 5 February 2013 Foreword EUCAST The European Committee on Antimicrobial Susceptibility Testing (EUCAST) is organised
More informationDiagnosis,Therapy and Prophylaxis of Fungal Diseases
mycoses Diagnosis,Therapy and Prophylaxis of Fungal Diseases Original article Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance â registry David L. Horn, 1 Alison
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationHigh risk neutropenic patient (anticipated duration > 10 days) Send blood twice weekly for Beta -D Glucan Galactomanan Aspergillus PCR
DERBY TEACHING HOSPITALS NHS FOUNDATION TRUST Prophylaxis, diagnosis and treatment of invasive fungal infections in oncology/haematology patients with prolonged neutropenia. High risk neutropenic patient
More informationESCMID Online Lecture Library. by author. CASE PRESENTATION ECCMID clinical grand round May Anat Stern, MD Rambam medical center Haifa, Israel
CASE PRESENTATION ECCMID clinical grand round May 2014 Anat Stern, MD Rambam medical center Haifa, Israel An 18 years old Female, from Ukraine, diagnosed with acute lymphoblastic leukemia (ALL) in 2003.
More informationCandida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital
Journal of Antimicrobial Chemotherapy (2005) 55, 188 193 doi:10.1093/jac/dkh532 Advance Access publication 13 January 2005 JAC Candida krusei fungaemia: antifungal susceptibility and clinical presentation
More informationSummary of the risk management plan (RMP) for Cresemba (isavuconazole)
EMA/576866/2015 Summary of the risk management plan (RMP) for Cresemba (isavuconazole) This is a summary of the risk management plan (RMP) for Cresemba, which details the measures to be taken in order
More informationOpen Forum Infectious Diseases Advance Access published February 11, 2016
Open Forum Infectious Diseases Advance Access published February 11, 2016 1 A Critical Reappraisal of Prolonged Neutropenia as a Risk Factor for Invasive Pulmonary Aspergillosis Michael S. Abers 1,2, Musie
More informationTRENDS IN INVASIVE FUNGAL INFECTIONS IN LIVER TRANSPLANT RECIPIENTS: CORRELATION WITH EVOLUTION IN TRANSPLANTATION PRACTICES
Transplantation Issue: Volume 73(1), 15 January 2002, p 63 67 Copyright: 2002 Lippincott Williams & Wilkins, Inc. Publication Type: [Clinical Transplantation] ISSN: 0041-1337 Accession: 00007890-200201150-00011
More informationLiposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients
ORIGINAL ARTICLE MYCOLOGY Liposomal amphotericin B twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients K. Bochennek 1, L. Tramsen 1, N. Schedler 1, M. Becker 1, T. Klingebiel
More informationHormographiella aspergillata: an emerging mould in acute leukaemia patients?
ORIGINAL ARTICLE MYCOLOGY Hormographiella aspergillata: an emerging mould in acute leukaemia patients? A. Conen 1, M. Weisser 2, D. Hohler 3, R. Frei 3 and M. Stern 4 1) Division of Infectious Diseases
More informationNo Evidence As Yet. Georg Maschmeyer. Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam, Germany
Is Combined Antifungal Therapy More Efficient than Single Agent Therapy? No Evidence As Yet www.ichs.org Georg Maschmeyer Dept. of Hematology, Oncology & Palliative Care Klinikum Ernst von Bergmann Potsdam,
More informationMicafungin, a Novel Antifungal Agent, as Empirical Therapy in Acute Leukemia Patients with Febrile Neutropenia
ORIGINAL ARTICLE Micafungin, a Novel Antifungal Agent, as Empirical Therapy in Acute Leukemia Patients with Febrile Neutropenia Masamitsu Yanada 1,2, Hitoshi Kiyoi 2, Makoto Murata 1, Momoko Suzuki 1,
More informationDiagnosis of Invasive Septate Mold Infections A Correlation of Microbiological Culture and Histologic or Cytologic Examination
Microbiology and Infectious Disease / DIAGNOSIS OF SEPTATE MOLD INFECTIONS Diagnosis of Invasive Septate Mold Infections A Correlation of Microbiological Culture and Histologic or Cytologic Examination
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationIsavuconazole. Lepak et al 2013 Antimicrob Agents Chemother 57: Lepak et al 2013 Antimicrob Agents Chemother 57:
Priv.-Doz. Dr. med. Maria J.G.T. Vehreschild Department I of Internal Medicine Clinical Trials Unit II Infectious Diseases Research Group Clinical Microbiome Isavuconazole 09.07.2017 Maria J.G.T. Vehreschild
More informationInvasive aspergillosis: Is treatment with inexpensive amphotericin B cost-saving if expensive voriconazole is only used on demand?
Original article Peer reviewed article SWISS MED WKLY 25;135:624 63 www.smw.ch 624 Invasive aspergillosis: Is treatment with inexpensive amphotericin B cost-saving if expensive voriconazole is only used
More informationReceived 22 November 2007/Returned for modification 29 December 2007/Accepted 12 January 2008
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2008, p. 1396 1400 Vol. 52, No. 4 0066-4804/08/$08.00 0 doi:10.1128/aac.01512-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. In Vitro
More informationHistorically, amphotericin B deoxycholate
OUR CURRENT UNDERSTANDING OF THERAPIES FOR INVASIVE FUNGAL INFECTIONS * John R. Perfect, MD ABSTRACT This article provides an update on the current state of the art for treating invasive fungal infections,
More information9/7/2018. Faculty. Overcoming Challenges in the Management of Invasive Fungal Infections. Learning Objectives. Faculty Disclosure
Faculty Overcoming Challenges in the Management of Invasive Fungal James S. Lewis II, PharmD, FIDSA ID Clinical Pharmacy Coordinator Oregon Health and Science University Departments of Pharmacy and Infectious
More informationImpact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis
Medical Mycology July 2012, 50, 538 542 Impact of the revised (2008) EORTC/MSG definitions for invasive fungal disease on the rates of diagnosis of invasive aspergillosis Dimitris A. Tsitsikas *, Amelie
More informationThe Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT
The Hospital for Sick Children Technology Assessment at SickKids (TASK) ABSTRACT CASPOFUNGIN IN THE EMPIRIC TREATMENT OF FEBRILE NEUTROPENIA IN PEDIATRIC PATIENTS: A COMPARISON WITH CONVENTIONAL AND LIPOSOMAL
More informationESCMID Online Lecture Library. by author. Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole
Salvage Therapy of Invasive Aspergillosis Refractory to Primary Treatment with Voriconazole J.A. Maertens, hematologist, MD, PhD University Hospital Gasthuisberg Leuven, Belgium Current guidelines: first-line
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More informationAdvances in the Understanding of the Pathogenesis of Opportinistic Fungal Diseases. Zygomycosis George L. Petrikkos
Advances in the Understanding of the Pathogenesis of Opportinistic Fungal Diseases. Zygomycosis George L. Petrikkos Professor of Internal Medicine and Infectious Disease National and Kapodistrian University
More informationMDS 1990, 1994, 1998, Fig. 1., Fig. 1, MDS, myelodysplastic syndrome 1989, 1993, ,
Jpn. J. Med. Mycol. Vol. 47, 15 24, 2006 ISSN 0916 4804 MDS 1990, 1994, 1998, 2002 1 2 3 4 1 1 1 2 3 4 8 29, 2005. 11 9, 2005 MDS,,., 27.9 435 /1,557, 1989, 23.0 319 /1,388, 1993, 22.3 246 /1,105, 1997,
More informationGJ Timmers 1, S Zweegman 1, AM Simoons-Smit 2, AC van Loenen 3, D Touw 3 and PC Huijgens 1. Summary:
(2000) 25, 879 884 2000 Macmillan Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nature.com/bmt Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections
More information